ImClone Systems
ImClone Systems Incorporated is a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and is headquartered in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL.
Read more about ImClone Systems: Insider Trading Scandal, Compassionate Use Controversy, Carl Icahn Acquisition, Takeover Offer From Bristol-Myers Squibb, and Subsequent Bidding Showdown, Yeda/Aventis/Imclone Patent Dispute
Famous quotes containing the word systems:
“The geometry of landscape and situation seems to create its own systems of time, the sense of a dynamic element which is cinematising the events of the canvas, translating a posture or ceremony into dynamic terms. The greatest movie of the 20th century is the Mona Lisa, just as the greatest novel is Gray’s Anatomy.”
—J.G. (James Graham)